BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

6.09
Delayed Data
As of Dec 04
 +0.95 / +18.50%
Today’s Change
1.58
Today|||52-Week Range
6.29
+76.38%
Year-to-Date
Why BioCryst Stock Is Crushing It Today
Dec 04 / MotleyFool.com - Paid Partner Content
Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?
Dec 03 / Zacks.com - Paid Partner Content
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
Dec 04 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close5.14
Today’s open5.85
Day’s range5.75 - 6.24
Volume1,747,670
Average volume (3 months)5,784,249
Market cap$904.0M
Data as of 7:33pm ET, 12/04/2020

Growth & Valuation

Earnings growth (last year)+4.00%
Earnings growth (this year)-2.99%
Earnings growth (next 5 years)+19.86%
Revenue growth (last year)+136.45%
P/E ratioNM
Price/Sales8.17
Price/Book20.62

Competitors

 Today’s
change
Today’s
% change
ARVNArvinas Inc+1.84+7.31%
CGENCompugen Ltd-0.09-0.70%
BTAIBioXcel Therapeutics...+0.20+0.44%
NKNantKwest Inc+0.24+2.61%
Data as of 3:59pm ET, 12/04/2020

Financials

Next reporting dateFebruary 24, 2021
EPS forecast (this quarter)-$0.22
Annual revenue (last year)$48.8M
Annual profit (last year)-$108.9M
Net profit margin-222.99%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Durham, North Carolina

Forecasts